Kyverna Therapeutics (KYTX) Institutional Ownership $4.12 +0.04 (+0.98%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Kyverna Therapeutics (NASDAQ:KYTX)CurrentInstitutional OwnershipPercentage18.08%Number ofInstitutional Buyers(last 12 months)38TotalInstitutional Inflows(last 12 months)$205.46MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$3.64M Get KYTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Kyverna Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data KYTX Institutional Buying and Selling by Quarter Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Kyverna Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC70,167$343K0.0%+21.5%0.163% 11/16/2024 Geode Capital Management LLC443,312$2.17M0.0%+19.0%1.027% 11/15/2024 Barclays PLC70,167$343K0.0%+21.5%0.163% 11/15/2024 XTX Topco Ltd52,792$258K0.0%-36.6%0.122% 11/15/2024 Jane Street Group LLC39,193$192K0.0%+78.3%0.091% 11/15/2024 Wellington Management Group LLP235,123$1.15M0.0%-67.0%0.545% Get the Latest News and Ratings for KYTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024 Sphera Funds Management LTD.248,651$1.22M0.2%+5.3%0.576% 11/15/2024 State Street Corp326,192$1.60M0.0%+3.2%0.756% 11/15/2024 Point72 Asset Management L.P.34,482$169K0.0%N/A0.080% 11/15/2024 Jacobs Levy Equity Management Inc.19,869$97K0.0%N/A0.046% 11/14/2024 Verition Fund Management LLC44,626$218K0.0%N/A0.103% 11/14/2024 UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC101,900$498K0.0%-11.7%0.236% 11/13/2024 BNP Paribas Financial Markets27,197$133K0.0%+2,166.4%0.063% 11/13/2024 FMR LLC6,692$33K0.0%N/A0.016% 11/12/2024 Charles Schwab Investment Management Inc.166,635$815K0.0%+33.2%0.386% 10/24/2024 Novo Holdings A S1,850,000$9.05M0.4%+5.7%4.291% 10/11/2024 Creative Planning11,028$54K0.0%N/A0.026% 8/26/2024 Teachers Retirement System of The State of Kentucky21,410$161K0.0%+69.7%0.050% 8/20/2024 Novo Holdings A S1,750,000$13.13M0.7%+150.0%4.059% 8/15/2024 The Manufacturers Life Insurance Company37,794$283K0.0%+32.6%0.088% 8/15/2024 Millennium Management LLC923,082$6.92M0.0%+32.8%2.141% 8/15/2024 MBB Public Markets I LLC410,191$3.08M0.1%N/A0.951% 8/15/2024 Deerfield Management Company L.P. Series C1,983,000$14.87M0.2%+35.6%4.599% 8/15/2024 Affinity Asset Advisors LLC200,000$1.50M0.2%N/A0.464% 8/14/2024 Great Point Partners LLC499,152$3.74M0.7%+232.8%1.158% 8/14/2024 Marshall Wace LLP10,400$78K0.0%-93.3%0.024% 8/13/2024 Skandinaviska Enskilda Banken AB publ26,195$196K0.0%+55.8%0.061% 8/12/2024 XTX Topco Ltd83,286$625K0.1%N/A0.193% 8/12/2024 E Fund Management Co. Ltd.189,432$1.42M0.1%N/A0.439% 8/10/2024 Sofinnova Investments Inc.47,850$359K0.0%+378.5%0.111% 8/8/2024 Federated Hermes Inc.16,000$120K0.0%N/A0.037% 8/3/2024 TD Asset Management Inc90,242$677K0.0%N/A0.209% 8/1/2024 Rhumbline Advisers20,007$150K0.0%N/A0.046% 7/26/2024 Bank of New York Mellon Corp55,790$418K0.0%N/A0.129% 6/4/2024 DekaBank Deutsche Girozentrale7,500$181K0.0%N/A0.017% 5/28/2024 Teachers Retirement System of The State of Kentucky12,614$313K0.0%N/A0.029% 5/17/2024 Artal Group S.A.200,000$4.97M0.1%N/A0.464% 5/16/2024 Janus Henderson Group PLC606,500$15.04M0.0%N/A1.407% 5/16/2024 Bain Capital Life Sciences Investors LLC3,163,868$78.59M6.3%N/A7.338% 5/16/2024 Blackstone Inc.100,000$2.48M0.0%N/A0.232% New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now!5/15/2024 Price T Rowe Associates Inc. MD929,634$23.09M0.0%N/A2.156% 5/15/2024 Avoro Capital Advisors LLC475,000$11.80M0.1%N/A1.102% 5/14/2024 StemPoint Capital LP41,000$1.02M0.3%N/A0.095% 5/10/2024 Vanguard Group Inc.264,215$6.56M0.0%N/A0.613% 5/2/2024 Jennison Associates LLC1,398,659$34.74M0.0%N/A3.244% (Data available from 1/1/2016 forward) KYTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of KYTX shares? During the previous two years, 41 institutional investors and hedge funds held shares of Kyverna Therapeutics. The most heavily invested institutionals were Bain Capital Life Sciences Investors LLC ($78.59M), Jennison Associates LLC ($34.74M), Price T Rowe Associates Inc. MD ($23.09M), Janus Henderson Group PLC ($15.04M), Deerfield Management Company L.P. Series C ($14.87M), Avoro Capital Advisors LLC ($11.80M), and Novo Holdings A S ($9.05M).Learn more on KYTX's institutional investors. What percentage of Kyverna Therapeutics stock is owned by institutional investors? 18.08% of Kyverna Therapeutics stock is owned by institutional investors. Learn more on KYTX's institutional investor holdings. Which institutional investors have been buying Kyverna Therapeutics stock? Of the 38 institutional investors that purchased Kyverna Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bain Capital Life Sciences Investors LLC ($3.16M), Jennison Associates LLC ($1.40M), Novo Holdings A S ($1.15M), Price T Rowe Associates Inc. MD ($929.63K), Janus Henderson Group PLC ($606.50K), Deerfield Management Company L.P. Series C ($520.66K), and Avoro Capital Advisors LLC ($475K). How much institutional buying is happening at Kyverna Therapeutics? Institutional investors have bought a total of 10,896,955 shares in the last 24 months. This purchase volume represents approximately $205.46M in transactions. Which Kyverna Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Kyverna Therapeutics stock in the last 24 months: Wellington Management Group LLP ($478.28K), Marshall Wace LLP ($145.36K), XTX Topco Ltd ($30.49K), and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($13.47K). How much institutional selling is happening at Kyverna Therapeutics? Institutional investors have sold a total of 667,591 shares in the last 24 months. This volume of shares sold represents approximately $3.64M in transactions. Related Companies TRDA Major Shareholders ABUS Major Shareholders CRMD Major Shareholders TECX Major Shareholders PHAT Major Shareholders EXAI Major Shareholders ORIC Major Shareholders ANAB Major Shareholders STOK Major Shareholders DNTH Major Shareholders This page (NASDAQ:KYTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
